Insights Dashboard
1L EGFR+ NSCLC. Twelve oncologists.
Synthesized themes, decision drivers, brand perceptions, and patient archetypes across all completed interviews. Click See source verbatim on any theme to drill into the respondent quote behind the claim.
Illustrative figures - synthetic, not real fieldwork. The numbers and quotes below are sample output that matches the shape the synthesis pipeline produces. Once Supabase is configured and the seed script has run (12 interviews → sagan.sessions / session_synthesis), this view aggregates the real completed sessions and flips to Live data.
- 12
- Interviews completed
- 18m 24s
- Avg duration
- 14.2
- Avg turns / session
- Intracranial efficacy
- Top driver
Decision Drivers
What actually tips the call.
Brand Perception Matrix
○ IllustrativeEfficacy vs tolerability.
Patient Archetypes
○ IllustrativeFour buckets, four different calls.
Young, fit, asymptomatic
→ Osimertinib monotherapy
Toxicity tradeoff doesn't justify combo for low-burden disease. Watchful escalation if/when progression.
Heavy CNS burden
→ MARIPOSA (amivantamab + lazertinib)
Intracranial activity is the discriminating factor - combo data is most compelling here.
Frail, ECOG 2+
→ Osimertinib monotherapy
Tolerability dominates. Even modest grade 3+ AEs lead to dose holds and discontinuation in this group.
High disease burden, fit
→ FLAURA2 (osimertinib + chemo)
PFS advantage matters when disease tempo is fast. Patient can tolerate the combo toxicity.
Top Themes
3 patterns. High signal.
10 of 12
CNS efficacy is decisive when present
“If they have brain mets, my conversation changes completely. I'm thinking MARIPOSA first now - the intracranial data is hard to argue with.”
9 of 12
Toxicity threshold drives combo hesitation
“FLAURA2 looks great on paper but in a community setting, the toxicity is real. I've had patients drop chemo within two cycles.”
7 of 12
Payer access shapes practice but doesn't dictate
“We get FLAURA2 approved most of the time, but the prior auth burden is real. MARIPOSA is harder. Osi mono is easy.”
Quote Reel
○ IllustrativeStandouts. In their words.
“I look at PFS, OS where available, and intracranial activity. That's the holy trinity.”
“Community oncology is different. We can't push toxicity the way an academic center can.”
“If the patient is asymptomatic with a single lung lesion, I'm not bringing chemo in. Period.”
“MARIPOSA's CNS data made me rethink everything for brain-met patients.”
“We're going to see real-world AEs that look different from the trial. The trial population is fitter.”
“If a patient says 'I want the strongest option,' we have a longer conversation about what 'strongest' means for THEM.”
Ask anything